Absence of p16/MTS1 gene mutations in human prostate cancer

Carcinogenesis

Volumn 17, Issue 12, 1996, Pages 2603-2607

  Chen, Wenwei ^a   Weghorst, Christopher M ^a   Sabourin, Carol L K ^a   Wang, Yian ^b   Wang, Dian ^a   Bostwick, David G ^c   Stoner, Gary D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ELECTROPHORETIC MOBILITY; EXON; HUMAN; HUMAN TISSUE; MALE; MUTATION RATE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

AGED; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATIC NEOPLASMS;

EID: 0030464202     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.12.2603     Document Type: Article

References (42)

1. Parker,S.L., Tong,T., Bolden,S. and Wingo,P.A. (1996) Cancer statistics, 1996. CA Cancer J. Clin., 46, 5-27.
2. Bosland,M.C. (1988) The etiopathogenesis of prostatic cancer with special reference to environmental factors. Adv. Cancer Res., 51, 1-106.
3. Bosland,M.C. (1986) Diet and cancer of the prostate: epidemiologic and experimental evidence. In Reddy,B.S. and Cohen,L.A. (eds), Diet, Nutrition and Cancer: A Critical Evaluation. CRC Press, Boca Raton, FL, pp. 125-149.
4. Catalona,W.J. (1984) Prostate Cancer. Grune & Stratton, Orlando, FL.
5. Sandberg,A.A. (1992) Cytogenetic and molecular genetic aspects of human prostate cancer: primary and metastatic. In Karr,J.P. and Yamanaka,H. (eds), Prostate Cancer and Bone Metastasis. Plenum Press, New York, pp. 45-75.
6. Isaacs,W.B., Bova,G.S., Morton,R.A., Bussemakers,M.J.G., Brooks,J.D. and Ewing,C.M. (1994) Molecular biology of prostate cancer. Semin. Oncol., 21, 514-521.
7. Sakr,W.A., Macoska,J.A., Benson,P., Grignon,D.J., Wolman,S.R., Edson Pontes,J. and Crissman,J.D. (1994) Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res., 54, 3273-3277.
8. Cooney,K.A., Wetzel,J.C., Merajver,S.D., Macoska,J.A., Singleton,T.P. and Wojno,K.J. (1996) Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res., 56, 1142-1145.
9. Gumerlock,P.H., Poonamallee,U.R., Meyers,F.J. and deVere White,R.W. (1991) Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res., 51, 1632-1637.
10. Moul,J.W., Friedrichs,P.A., Lance,R.S., Theune,S.M. and Chang,E.H. (1992) Infrequent Ras oncogene mutations in human prostate cancer. Prostate, 20, 327-338.
11. Brooks,J.D., Bova,G.S. and Isaacs,W.B. (1995) Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate, 26, 35-39.
12. Bookstein,R., Rio,P., Madreperla,S.A., Hong,F., Allred,C., Grizzle,W.E. and Lee,W.H. (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc. Natl Acad. Sci. USA, 87, 7762-7766.
13. Bookstein,R., Shew,J.Y., Chen,P.L., Scully,P. and Lee,W.H. (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene. Science, 247, 712-715.
14. Ittmann,M., Wieczorek,R., Heller,P., Dave,A., Provet,J. and Krolewski,J. (1994) Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am. J. Pathol., 145, 287-293.
15. Bookstein,R., MacGrogan,D., Hilsenbeck,S.G., Sharkey,F. and Allred,C.D. (1993) p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53, 3369-3373.
16. Kamb,A. et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440.
17. Nobori,T., Miura,K., Wu,D.J., Lois,A., Takabayashi,K. and Carson,D.A. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756.
18. Peters,G. (1994) Stifled by inhibitions. Nature, 371, 204-205.
19. Mori,T., Miura,K., Aoki,T., Nishihira,J., Mori,S. and Nakamura,Y. (1994) Frequent somatic mutations of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase-4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397.
20. Hayashi,N., Sugimoto,Y., Tsuchiya,E., Ogawa,M. and Nakamura,Y. (1994) Somatic mutations of MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Commun., 202, 1426-1430.
21. ink4) in human breast carcinoma. Cancer Res., 54, 5262-5264.
22. Brenner,A.J. and Aldaz,C.M. (1995) Chromosome 9p allelic loss and p16/ CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res., 55, 2892-2895.
23. Zhang,S.Y., Klein-Szanto,A.J.P., Sauter,E.R., Shafarenko,M., Mitsunaga,S., Nobori,T., Carson,D.A., Ridge,J.A. and Goodrow,T.L. (1994) Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54, 5050-5053.
24. Cairns,P. et al. (1994) Rates of p16 (MTSI) mutations in primary tumors with 9p loss. Science, 265, 415-417.
25. Spruck,C.H., Gonzalez-Zulueta,M., Shibata,A., Simoneau,A.R., Lin,M.F., Gonzales,F., Tsai,Y.C. and Jones,P.A. (1994) p16 gene in uncultured tumors. Nature, 370, 183-184.
26. Ohta,M. et al. (1994) Rarity of somatic and germline mutations of the cyclin dependent kinase 4 inhibitor gene. CDK41, in melanoma. Cancer Res., 54, 5269-5272.
27. Miller,S.A., Dykes,D.D. and Polesky,H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res., 16, 1215.
28. Sardelli,A.D. (1993) Plateau effect - understanding PCR limitations. Amplifications, 9, 3-5.
29. Lane,K.B., Zoia,O. and Davidson,J.M. (1992) Semidry electrophoretic transfer of RNA to membranes. BioTechniques, 12, 340-343.
30. Hongyo,T., Buzard,G.S., Calvert,R.J. and Weghorst,C.M. (1993) 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res., 21, 3637-3642.
31. Hussussian,C.J., Struewing,J.P., Goldstein,A.M., Higgins,P.A.T., Ally,D.S., Sheahan,M.D., Clark,W.H., Jr, Tucker,M.A. and Dracopoli,N.C. (1994) Germline p16 mutations in familial melanoma. Nature Genet., 8, 15-21.
32. Knudson,A.G., Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA, 68, 820-823.
33. Walker,D.G., Duan,W., Popovic,E.A., Kaye,A.H., Tomlinson,F.H. and Lavin,M. (1995) Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res., 55, 20-23.
34. Visakorpi,T., Kallioniemi,A.H., Syvänen,A.C., Hyytinen,E.R., Karhu,R., Tammela,T., Isola,J.J. and Kallioniemi,O.P. (1995) Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res., 55, 342-347.
35. Cher,M.L., MacGrogan,D., Bookstein,R., Brown,J.A., Jenkins,R.B. and Jensen,R.H. (1994) Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer, 11, 153-162.
36. Xiao,S., Renshaw,A., Cibas,E.S., Hudson,T.J. and Fletcher,J.A. (1995) Novel fluorescence in situ hybridization approaches in solid tumors. Characterization of frozen specimens, touch preparations, and cytological preparations. Am. J. Pathol., 147, 896-904.
37. Liu,Q. et al. (1995) CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncagene, 10, 1061-1067.
38. Komiya,A., Suzuki,H., Aida,S., Yatani,R. and Shimazaki,J. (1995) Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn. J. Cancer Res., 86, 622-625.
39. Konishi,N., Enomoto,T., Buzard,G., Ohshima,M., Ward,J.M. and Rice,J.M. (1992) K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer, 69, 2293-2298.
40. Anwar,K., Nakakuki,K., Shiraishi,T., Naiki,H., Yatani,R. and Inuzuka,M. (1992) Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res., 52, 5991-5996.
41. Herman,J.G., Merlo,A., Mao,L., Lapidus,R.G., Issa,J.J., Davidson,N.E., Sidransky,D. and Baylin,S.B. (1995) Inactivation of the CDK2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55, 4525-4530.
42. Merlo,A., Herman,J.G., Mao,L., Lee,D.J., Gabrielson,E., Burger,P.C., Baylin,S.B. and Sidransky,D. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med., 1, 686-692.